SELECT * FROM `stock_list` where symbol='A1LN34' AND exchange = 'BSP' limit 0,1
SELECT * FROM `stock_list` where symbol='A1LN34' AND exchange = 'BSP' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "A1LN34" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 Alnylam Pharmaceuticals (BSP:A1LN34) Dividend Yield %
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Dividend Yield %

Alnylam Pharmaceuticals (BSP:A1LN34) Dividend Yield % : 0.00% (As of May. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Dividend Yield %?

As of today (2024-05-01), the Trailing Annual Dividend Yield of Alnylam Pharmaceuticals is 0.00%.

The historical rank and industry rank for Alnylam Pharmaceuticals's Dividend Yield % or its related term are showing as below:

BSP:A1LN34's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.495
* Ranked among companies with meaningful Dividend Yield % only.

Alnylam Pharmaceuticals's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00.

As of today (2024-05-01), the Forward Dividend Yield % of Alnylam Pharmaceuticals is 0.00%.

Alnylam Pharmaceuticals's Dividends per Share for the three months ended in Dec. 2023 was R$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Alnylam Pharmaceuticals Dividend Yield % Historical Data

The historical data trend for Alnylam Pharmaceuticals's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Dividend Yield % Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alnylam Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alnylam Pharmaceuticals's Dividend Yield %

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Dividend Yield % falls into.



Alnylam Pharmaceuticals Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Alnylam Pharmaceuticals  (BSP:A1LN34) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Alnylam Pharmaceuticals Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines